CoChat

Elevated levels of circulating CDH5 and FABP1 in association with human drug‐induced liver injury

Open access
Mikus, Maria, Drobin, Kimi, Gry, Marcus, Bachmann, Julie, Lindberg, Johan, Yimer, Getnet, Aklillu, Eleni, Makonnen, Eyasu, Aderaye, Getachew, Roach, James, Fier, Ian, Kampf, Caroline, Göpfert, Jens, Perazzo, Hugo, Poynard, Thierry, Stephens, Camilla, Andrade, Raúl J., Lucena, M Isabel, Arber, Nadir, Uhlén, Mathias, Watkins, Paul B., Schwenk, Jochen M., Nilsson, Peter, Schuppe‐Koistinen, Ina · 2017 · Liver International
Cited by 40

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Background & Aims: The occurrence of drug‐induced liver injury (DILI) is a major issue in all phases of drug development. To identify novel biomarker candidates associated with DILI, we utilised an affinity proteomics strategy, where antibody suspension bead arrays were applied to profile plasma and serum samples from human DILI cases and controls. Methods: An initial screening was performed using 4594 randomly selected antibodies, representing 3450 human proteins. Resulting candidate proteins together with proposed DILI biomarker candidates generated a DILI array of 251 proteins for subsequent target analysis and verifications. In total, 1196 samples from 241 individuals across four independent cohorts were profiled: healthy volunteers receiving acetaminophen, patients with human immunodeficiency virus and/or tuberculosis receiving treatment, DILI cases originating from a wide spectrum of drugs, and healthy volunteers receiving heparins. Results: We observed elevated levels of cadherin 5, type 2 (CDH 5) and fatty acid‐binding protein 1 (FABP 1) in DILI cases. In the two longitudinal cohorts, CDH 5 was elevated already at baseline. FABP 1 was elevated after treatment initiation and seemed to respond more rapidly than alanine aminotransferase (ALT). The elevations were verified in the DILI cases treated with various drugs. In the heparin cohort, CDH 5 was stable over time whereas FABP 1 was elevated. Conclusions: These results suggest that CDH 5 may have value as a susceptibility marker for DILI. FABP 1 was identified as a biomarker candidate with superior characteristics regarding tissue distribution and kinetics compared to ALT but likely with limited predictive value for the development of severe DILI. Further studies are needed to determine the clinical utility of the proposed markers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/liv.13174

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 40

Metadata

Authors
Mikus, M., Drobin, K., Gry, M., Bachmann, J., Lindberg, J., Yimer, G., Aklillu, E., Makonnen, E., Aderaye, G., Roach, J., Fier, I., Kampf, C., Göpfert, J., Perazzo, H., Poynard, T., Stephens, C., Andrade, R. J., Lucena, M. I., Arber, N., Uhlén, M., Watkins, P. B., Schwenk, J. M., Nilsson, P., & Schuppe‐Koistinen, I.
Venue
Liver International
Publisher
Wiley
Published
2016-06-22
Volume
37
Issue
1
Pages
132-140
ISSN
  • 0106-9543 (ISSN-L)
  • 1478-3223
  • 1478-3231
OpenAlex
W2401008396
Cited by
40
References
2
FWCI
6.29
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Elevated levels of circulating CDH5 and FABP1 in association with human drug‐induced liver injury. https://app.cochat.ai/papers/10.1111/liv.13174
The paper
Mikus, M., Drobin, K., Gry, M., Bachmann, J., Lindberg, J., Yimer, G., Aklillu, E., Makonnen, E., Aderaye, G., Roach, J., Fier, I., Kampf, C., Göpfert, J., Perazzo, H., Poynard, T., Stephens, C., Andrade, R. J., Lucena, M. I., Arber, N., . . . Schuppe‐Koistinen, I. (2017). Elevated levels of circulating CDH5 and FABP1 in association with human drug‐induced liver injury. Liver International. https://doi.org/10.1111/liv.13174

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.